Angelini Pharma never stops looking at future, with a foremost attention to innovative solutions and opportunities for identifying and enhancing promising health solutions.
That’s why the company has joined other focal European investors in supporting Argobio SAS, a French start-up studio that is going to create and launch at least five ambitious biotech companies over the next five years, sourcing innovative early-stage projects from prominent European academic research institutions. Argobio will focus on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. The investors will have the unique opportunity to participate in the biotech companies created by Argobio. The launch takes place with 50 M€ of committed capital.
Argobio will identify, select, and incubate these projects up to company creation, providing broad expertise in the discovery and development of innovative therapeutic products from its team of highly experienced biotech entrepreneurs.
Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Besides Angelini Pharma, the other complementary strategic investors are Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.